Anti-angiogenic therapy for osteosarcoma

Cancer and Metastasis Reviews

Volumn 25, Issue 4, 2006, Pages 707-713

  Quan, Gerald M Y ^a,b   Choong, Peter F M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Anti angiogenic; Cancer; Cartilage; Osteosarcoma; Therapy

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ENDOSTATIN; METALLOPROTEINASE; PIGMENT EPITHELIUM DERIVED FACTOR; THROMBOSPONDIN 2; TROPONIN I;

ANGIOGENESIS; CANCER INVASION; CELL MIGRATION; CLINICAL TRIAL; HUMAN; HYALINE CARTILAGE; METASTASIS; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; EYE PROTEINS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NERVE GROWTH FACTORS; OSTEOSARCOMA; SERPINS;

EID: 33846109280     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-006-9031-1     Document Type: Review

References (62)

1. Renard, A. J., Veth, R. P., Schreuder, H. W., Pruszczynski, M., Bokkerink, J. P., van Hoesel, Q. G., et al. (1999). Osteosarcoma: Oncologic and functional results. A single institutional report covering 22 years. Journal of Surgical Oncology, 72, 124-129.
2. Bacci, G., Ferrari, S., Bertoni, F., Ruggieri, P., Picci, P., Longhi, A., et al. (2000). Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 protocol: An updated report. Journal of Clinical Oncology, 18, 4016-4027.
3. Thompson, W. D., Shiach, R. J., Fraser, R. A., McIntosh, L., & Simpson, J. G. (1987). Tumors acquire their vasculature by vessel incorporation not vessel ingrowth. Journal of Pathology, 151, 323-332.
4. Folkman, J. (1992). The role of angiogenesis in tumor growth. Seminars in Cancer Biology, 3, 65-71.
5. Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. New England Journal of Medicine, 285, 1182-1186.
6. Dvorak, H. F., Sioussat, T. M., Brown, L. F., Berse, B., Nagy, J. A., Sotrel A., et al. (1991). Distribution of vascular endothelial growth factor in tumors; concentration in tumor blood vessels. Journal of Experimental Medicine, 174, 1275-1278.
7. Folkman, J. (1995). Clinical applications of research on angiogenesis. New England Journal of Medicine, 333, 1757-1763.
8. Dano, K., Aldreasen, P. A., Grondhal-Hansen, J., Kristensen, P., Nielsen, L. S., & Skriver, L. (1985). Plasminogen activators, tissue degradation, and cancer. Advances in Cancer Research, 44, 139-226.
9. Gee, M. S., Koch, C. J., Evans, S. M., Jenkins, W. T., Pletcher, C. H., Moore, J. S., et al. (1999). Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Research, 59, 4882-4889.
10. Lee, Y. H., Tokunaga, T., Oshika, Y., Suto, R., Yanagisawa, K., Tomisawa, M., et al. (1999). Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. European Journal of Cancer, 35, 1089-1093.
11. Handa, A., Tokunaga, T., Tsuchida, T., Lee, Y. H., Kijima, H., Yamazaki, H., et al. (2000). Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma. International Journal of Oncology, 17, 291-295.
12. Kaya, M., Wada, T., Akatsuka, T., Kawaguchi, S., Nagoya, S., Shindoh, M., et al. (2000). Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clinical Cancer Research, 6, 572-577.
13. El-Houseini, M. E., Abdel-Azim, S. A., El-Desouky, G. I., Abdel-Hady, S., El-Hamad, M. F., & Kamel, A. M. (2004). Clinical significance of vascular endothelial growth factor (VEGF) in sera of patients with pediatric malignancies. Journal of Egyptian National Cancer Institute, 16, 57-61.
14. Franchi, A., Arganni, L., Baroni, G., Calzolari, A., Capanna, R., Campanacci, D., et al. (1998). Expression of transforming growth factor b isoforms in osteosarcoma variants: Association of TGFb1 with high-grade osteosarcomas. Journal of Pathology, 185, 284-289.
15. Mantadakis, E., Kim, G., Reisch, J., McHard, K., Maale, G., Leavey, P. J., et al. (2001). Lack of prognostic significance of imtratumoral angiogenesis in nonmetastatic osteosarcoma. Journal of Pediatric Hematology/Oncology, 23, 286-289.
16. Mikulic, D., Ilic, I., Cepulic, M., Orlic, D., Gilevic, J. S., Fattorini, I., et al. (2004). Tumor angiogenesis and outcome in osteosarcoma. Pediatric Hematology and Oncology, 21, 611-619.
17. Kreuter, M., Bieker, R., Bielack, S. S., Auras, T., Buerger, H., Gosheger, G., et al. (2004). Prognostic relevance of increased angiogenesis in osteosarcoma. Clinical Cancer Research, 10, 8531-8537.
18. Friedman, M. A., & Carter, S. K. (1972). The therapy of osteogenic sarcoma: Current status and thoughts for the future. Journal of Surgical Oncology, 4, 482-510.
19. Synder, C. L., Saltsman, D. A., Ferell, K. L., Thompson, R. C., & Leonard, A. S. (1991). A new approach to the resection of pulmonary osteosarcoma metastasis: Results of aggressive metastectomy. Clinical Orthopaedics, 270, 247-253.
20. O'Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Natural Medicines, 2, 689-692.
21. Tsunemi, T., Nagoya, S., Kaya, M., Kawaguchi, S., Wada, T., Yamashita, T., et al. (2003). Postoperative progression of pulmonary metastasis in osteosarcoma. Clinical Orthopaedics, 407, 159-166.
22. Kaya, M., Wada, T., Nagoya, S., Kawaguchi, S., Isu, K., & Yamashita, T. (2004). Concomitant tumor resistance in patients with osteosarcoma. A clue to a new therapeutic strategy. Journal of Bone and Joint Surgery. British, 86, 143-147.
23. Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y. N., et al. (1994). Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. International Journal of Cancer, 57, 920-925.
24. Kato, T., Sato, K., Kakinuma, H., & Matsuda, Y. (1994). Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Research, 54, 5143-5147.
25. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., et al. (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. Journal of Clinical Investigation, 105, 15-24.
26. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., et al. (1994). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315-328.
27. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., et al. (1997). Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-285.
28. Yokoyama, Y., Green, J. E., Sukhatme, V. P., & Ramakrishnan, S. (2000). Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Research, 60, 4362-4365.
29. Yokoyama, Y., Dhanabal, M., Griffioen, A. W., Sukhatme, V. P., & Ramakrishnan, S. (2000). Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth. Cancer Research, 60, 2190-2196.
30. Chen, C. T., Lin, J., Li, Q., Phipps, S. S., Jakubczak, J. L., Stewart, D. A., et al. (2000). Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Human Gene Therapy, 11, 1983-1996.
31. Furumatsu, T., Yamaguchi, N., Nishida, K., Kawai, A., Kunisada, T., Namba, M., et al. (2002). Endostatin inhibits adhesion of endothelial cells to collagen I via alpha(2)beta(1) integrin, a possible cause of prevention of chondrosarcoma growth. Journal of Biochemistry, 131, 619-626.
32. Dutour, A., Monteil, J., Paraf, F., Charissoux, J. L., Kaletta, C., Sauer, B., et al. (2005). Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: Study in a human-like rat orthotopic tumor. Molecular Therapy, 11, 311-319.
33. Mundhenke, C., Thomas, J. P., Wilding, G., Lee, F. T., Kelzc, F., Chappell, R., et al. (2001). Tissue examination to monitor antiangiogenic therapy: A phase I clinical trial with endostatin. Clinical Cancer Research, 7, 3366-3374.
34. Thomas, J. P., Arzoomanian, R. Z., Alberti, D., Marnocha, R., Lee, F., Friedl, A., et al. (2003). Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. Journal of Clinical Oncology, 21, 223-231.
35. Quan, G. M., Slavin, J. L., Schlicht, S. M., Smith, P. J., Powell, G. J., & Choong, P. F.(2005). Osteosarcoma near joints: Assessment and implications. Journal of Surgical Oncology, 91, 159-166.
36. Quan, G. M., Ojaimi, J., Nadesapillai, A. P., Zhou, H., & Choong, P. F.(2003). Resistance of epiphyseal cartilage to invasion by osteosarcoma is likely to be due to expression of antiangiogenic factors. Pathobiology, 70, 361-367.
37. Moses, M. A., Sudhalter, J., & Langer, R. (1990). Identification of an inhibitor of neovascularization from cartilage. Science, 248, 1408-1410.
38. Kyriakides, T. R., Zhu, Y., Yang, Z., & Bornstein, P. (1998). The distribution of the matricellular protein thrombospondin 2 in tissues of embryonic and adult mice. Journal of Histochemistry and Cytochemistry, 46, 1007-1015.
39. Shukunami, C., Iyama, K., Inoue, H., & Hirakim, Y. (1999). Spatiotemporal pattern of the mouse chondromodulin-I gene expression and its regulatory role in vascular invasion into cartilage during endochondral bone formation. International Journal of Developmental Biology, 43, 39-49.
40. Moses, M. A., Wiederschain, D., Wu, I., Fernandez, C. A., Ghazizadeh, V., Lane, W. S., et al. (1999). Troponin I is present in human cartilage and inhibits angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 96, 2645-2650.
41. Cheung, W. H., Lee, K. M., Fung, K. P., Lui, P. Y., & Leung, K. S. (2001). TGF-b1 is the factor secreted by proliferative chondrocytes to inhibit neo-angiogenesis. Journal of Cellular Biochemistry. Supplement, 36, 79-88.
42. Hayami, T., Shukunami, C., Mitsui, K., Endo, N., Tokunaga, K., Kondo, J., et al. (1999). Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo. FEBS Letters, 458, 436-440.
43. Dutour, A., Rabinovich-Chable, H., Kaletta, C., Michaelis, U., Fiorenze, F., Sturtz, F., et al. (2004). Is troponin I gene therapy effective for osteosarcoma treatment? Study on a human-like orthotopic rat model. Anticancer Research, 24, 3977-3982.
44. Streit, M., Riccardi, L., Velasco, P., Brown, L. F., Hawighorst, T., Bornstein, P., et al. (1999). Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 96, 14888-14893.
45. Dupont, E., Falardeau, P., Mousa, S. A., Dimitriadou, V., Pepin, M. C., Wang, T., et al. (2002). Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clinical & Experimental Metastasis, 19, 145-153.
46. Weber, M. H., Lee, J., & Orr, F. W. (2002). The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. International Journal of Oncology, 20, 299-303.
47. Falardeau, P., Champagne, P., Poyet, P., Hariton, C., & Dupont, E. (2001). Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Seminars in Oncology, 28, 620-625.
48. Latreille, J., Batist, G., Laberge, F., Champagne, P., Croteau, D., Falardeau, P., et al. (2003). Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clinical Lung Cancer, 4, 231-236.
49. Miller, D. R., Anderson, G. T., Stark, J. J., Granick, J. L., & Richardson, D. (1998). Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. Clinical Oncology, 16, 3649-3655.
50. Loprinzi, C. L., Levitt, R., Barton, D. L., Sloan, J. A., Atherton, P. J., Smith, D. J., et al. (2005). Evaluation of shark cartilage in patients with advanced cancer: A North Central Cancer Treatment Group trial. Cancer, 104, 176-182.
51. Steele, F. R., Chader, G. J., Johnson, L. V., & Tombran-Tink, J. (1993). Pigment epithelium-derived factor: Neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proceedings of the National Academy of Sciences of the United States of America, 90, 1526-1530.
52. Houenou, L. J., D'Costa, A. P., Li, L., Turgeon, V. L., Enyadike, C., Alberdi, E., et al. (1999). Pigment epithelium-derived factor promotes the survival and differentiation of developing spinal motor neurons. Journal of Comparative Neurology, 412, 506-514.
53. Pignolo, R. J., Cristofalo, V. J., & Rotenberg, M. O. (1993). Senescent WI-38 cells fail to express EPC-1, a gene induced in young cells upon entry into the G0 state. Journal of Biological Chemistry, 268, 8949-8957.
54. Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E., Xu, H., Benedict, W., et al. (1999). Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science, 285, 245-248.
55. Doll, J. A., Stellmach, V. M., Bouck, N. P., Bergh, A. R., Lee, C., Abramson, L. P., et al. (2003). Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Natural Medicines, 12, 774-780.
56. Tombran-Tink, J., Mazuruk, K., Rodriguez, I. R., Chung, D., Linker, T., Englander, E., et al. (1996). Organization, evolutionary conservation, expression and unusual Alu density of the human gene for pigment epithelium-derived factor, a unique neurotrophic serpin. Molecular Vision, 2, 1-11.
57. Quan, G. M., Ojaimi, J., Li, Y., Kartsogiannis, V., Zhou, H., & Choong, P. F. (2005). Localization of pigment epithelium-derived factor in growing mouse bone. Calcified Tissue International, 76, 146-153.
58. Guan, M., Yam, H. F., Su, B., Chan, K. P., Pang, C. P., Liu, W. W., et al. (2003). Loss of pigment epithelium derived factor expression in glioma progression. Journal of Clinical Pathology, 56, 277-282.
59. Crawford, S. E., Stellmach, V., Ranalli, M., Huang, X., & Huang, L., Volpert, O., et al. (2001). Pigment epithelium-derived factor (PEDF) in neuroblastoma: A multifunctional mediator of Schwann cell antitumor activity. Journal of Cell Science, 114, 4421-4428.
60. Mahtabifard, A., Merritt, R. E., Yamada, R. E., Crystal, R. G., & Korst, R. J. (2003). In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. Journal of Thoracic and Cardiovascular Surgery, 126, 28-38.
61. Wang, L., Schmitz, V., Perez-Mediavilla, A., Izal, I., Prieto, J., & Qian, C. (2003). Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Molecular Therapy, 8, 72-79.
62. Abramson, L. P., Stellmach, V., Doll, J. A., Cornwell, M., Arensman, R. M., & Crawford, S. E. (2003). Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model. Journal of Pediatric Surgery, 38, 336-342.